Ovid reports Takeda presented interim soticlestat data at AAN meeting

Ovid Therapeutics (OVID) reports that Takeda Pharmaceuticals (TAK) presented interim data at the 2023 annual meeting of the American Academy of Neurology, or AAN, from ENDYMION 1, a long-term, open label extension study evaluating the effects of soticlestat on patients with Dravet syndrome, or DS, and Lennox-Gastaut syndrome, or LGS. "The findings reaffirm soticlestat was generally safe and well tolerated. Soticlestat additionally showed an encouraging median seizure reduction in both conditions," Ovid stated. Key findings were: Approximately 78% of patients tolerated the highest dose level well. The majority of TEAEs were mild or moderate in severity. Drug-related TEAEs occurring in greater than 5% of patients were decreased appetite, seizure and somnolence. Soticlestat demonstrated a sustained reduction in frequency of convulsive and drop seizures from baseline up to 2 years. At weeks 1-12, 49-60, and 97-108 median changes in Dravet patients’ convulsive seizures was respectively: -33.7%; -47.8, -58.2. In LGS patients, the median change in drop seizures at weeks 1-12, 49-60, and 97-108 was respectively: -29.3%, -14.1%, -36.6%. At weeks 1-12, 49-60, and 97-108 median changes in all seizure frequency from baseline were -28.0%, -59.6%, and -53.4% in DS patients, respectively, and -28.4%, -17.7%, and -27.7% in LGS patients, respectively.